[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-detail-182177-en":3,"doc-seo-182177-105":29,"detail-sidebar-cat-0-en-105":95},{"code":4,"msg":5,"data":6},0,"success",{"doc_id":7,"user_id":8,"nickname":9,"user_avatar":10,"doc_module":4,"category_id":11,"category_name":12,"doc_title":13,"doc_description":14,"doc_content":15,"file_id":16,"file_url":17,"file_type":18,"file_size":19,"view_count":20,"is_deleted":4,"is_public":20,"is_downloadable":20,"audit_status":20,"page_count":11,"language":21,"language_code":22,"site_id":23,"html_lang":22,"table_of_contents":24,"faqs":25,"seo_title":26,"seo_description":14,"update_tm":27,"read_time":28},182177,7971461740909,"Levi","https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d",4,"Exam","Reading Part A - Text Booklet - Sample Test 5","Reading Part A Text Booklet Sample Test 5 provides candidate-facing instructions and a candidate declaration for an OET assessment. It includes rules on not removing test materials, guidance for filling in the candidate number using a 2B pencil, and a signature-based agreement on test content confidentiality and compliance. The booklet also contains clinical classification guidance (Classes I-IV) for cellulitis severity and outlines suitable drug therapies, including first- and second-line options for typical and atypical cases with penicillin allergy considerations.","| \u003Cbr>READING PART A: TEXT BOOKLET |  |  |  |  |\n| --- | --- | --- | --- | --- |\n| CANDIDATE NAME: |  |  |  |  |\n| D.O.B.: | D D M M Y Y Y Y |  | PROFESSION:\u003Cbr>TEST DATE: |  |\n| VENUE: |  |  |  |  |\n| |  | Starting at the left, print your Candidate Number and fill in the corresponding circle below each number using a 2B pencil.\u003Cbr>|  | CANDIDATE DECLARATION\u003Cbr>By signing this, you agree not to disclose or use in any way (other than to take the test) or assist any other person to disclose or use any OET test or sub-test content. If you cheat or assist in any cheating, use any unfair practice, break any of the rules or regulations, or ignore any advice or information, you may be disqualified and your results may not be issued at the sole discretion of CBLA. CBLA also reserves its right to take further disciplinary action against you and to pursue any other remedies permitted by law. If a candidate is suspected of and investigated for malpractice, their personal details and details of the investigation may be passed to a third party where required.\u003Cbr>CANDIDATE SIGNATURE: |\n\n\n| INSTRUCTIONS TO CANDIDATES |\n| --- |\n| You must NOT remove OET material from the test room. |\n\n| Class I | There are no signs of systemic toxicity, and the person has no uncontrolled co-morbidities. |\n| --- | --- |\n| Class II | The person is either systemically unwell or systemically well but with a co-morbidity, e.g., peripheral arterial disease, chronic venous insufficiency, or morbid obesity, which may complicate or delay resolution of infection. |\n| Class III | The person has significant systemic upset such as acute confusion, tachycardia or hypotension, or a limb-threatening infection due to vascular compromise. |\n| Class IV | The person has a severe life-threatening infection such as necrotizing fasciitis. |\n\n| Suitable drug | therapy for typical cellulitis |  |\n| --- | --- | --- |\n|  | First line | Second line |\n| Class 1 | Flucloxacillin 500 mg 4x/day PO | Penicillin allergy: Clarithromycin 300 mg 2x/day PO |\n| Class 2 | Flucloxacillin 1 g 4x/day IV\u003Cbr>or\u003Cbr>* Ceftriaxone 1 g 1x/day IV (OPAT only)(Must not be used in penicillin anaphylaxis) | Penicillin allergy:\u003Cbr>Clarithromycin 500 mg 2x/day IVor Clindamycin 600 mg 4x/day IV |\n| Class 3 | Flucloxacillin 1 g 4x/day IV | Penicillin allergy:\u003Cbr>Clarithromycin 500 mg 2x/day IVor Clindamycin 600 mg 4x/day IV |\n| Class 4 | Benzylpenicillin 2.4 g 2-4 hourly IV\u003Cbr>+ Ciprofloxacin 400 mg 2x/day IV\u003Cbr>+ Clindamycin 600 mg–1.2 g 4x/day (If allergic to penicillin use Ciprofloxacin and Clindamycin only) NB: Discuss with local Medical Microbiology Service |  |\n| Suitable drug therapy for atypical cellulitis |  |  |\n| Risk Factor | First line | Penicillin allergy |\n| Human bite | Co-amoxiclav 625 mg 3x/day PO | Clarithromycin 500 mg 2x/day POor Doxycycline 100 mg 2x/day PO and Metronidazole 400 mg 3x/day PO |\n| Cat/dog bite | Co-amoxiclav 625 mg 3x/day PO | Doxycycline 100 mg 2x/day PO and Metronidazole 400 mg 3x/day PO |\n| Exposure to fresh water at site of skin break | Ciprofloxacin 750 mg 2x/day PO and Flucloxacillin 500 mg 4x/day PO | Ciprofloxacin 750 mg 2x/day PO and Clarithromycin 500 mg 2x/day PO |","cbCaimt8jpFKlkik","https://ap.wps.com/l/cbCaimt8jpFKlkik","pdf",872741,1,"English","en",105,"# INSTRUCTIONS TO CANDIDATES\n# CANDIDATE DECLARATION\n# Class I-IV\n## Suitable drug therapy for typical cellulitis\n## Suitable drug therapy for atypical cellulitis","[{\"question\":\"What restriction is stated in the instructions to candidates?\",\"answer\":\"Candidates must not remove OET material from the test room.\"},{\"question\":\"What does the candidate declaration require regarding test content?\",\"answer\":\"By signing, candidates agree not to disclose or use any OET test or sub-test content except to take the test, and not to assist others to disclose or use it.\"},{\"question\":\"How is cellulitis severity classified in the booklet?\",\"answer\":\"It uses Classes I to IV, ranging from no systemic toxicity (Class I) through systemic unwell states with comorbidity (Class II), significant systemic upset or vascular-compromised limb infection (Class III), to severe life-threatening infections like necrotizing fasciitis (Class IV).\"}]","Reading Part A - Text Booklet - Sample Test 5 | PDF",1788347480,10,{"code":4,"msg":30,"data":31},"ok",{"site_id":23,"language":22,"slug":32,"title":13,"keywords":33,"description":14,"schema_data":34,"social_meta":90,"head_meta":92,"extra_data":94,"updated_unix":27},"reading-part-a-text-booklet-sample-test-5","",{"@graph":35,"@context":89},[36,52,72],{"@type":37,"itemListElement":38},"BreadcrumbList",[39,43,47,50],{"item":40,"name":41,"@type":42,"position":20},"https://docshare.wps.com","Home","ListItem",{"item":44,"name":45,"@type":42,"position":46},"https://docshare.wps.com/document/","Document",2,{"item":48,"name":12,"@type":42,"position":49},"https://docshare.wps.com/document/exam/",3,{"item":51,"name":13,"@type":42,"position":11},"https://docshare.wps.com/document/reading-part-a-text-booklet-sample-test-5/182177/",{"url":51,"name":13,"@type":53,"image":54,"author":59,"headline":13,"publisher":61,"fileFormat":64,"inLanguage":22,"description":14,"dateModified":65,"datePublished":66,"encodingFormat":64,"isAccessibleForFree":67,"interactionStatistic":68},"DigitalDocument",{"url":55,"@type":56,"width":57,"height":58},"https://docshare.wps.com/thumbnails/reading-part-a-text-booklet-sample-test-5/182177.png","ImageObject",300,407,{"name":9,"@type":60},"Person",{"url":40,"name":62,"@type":63},"DocShare","Organization","application/pdf","2026-09-11","2026-09-02",true,{"@type":69,"interactionType":70,"userInteractionCount":20},"InteractionCounter",{"@type":71},"ViewAction",{"@type":73,"mainEntity":74},"FAQPage",[75,81,85],{"name":76,"@type":77,"acceptedAnswer":78},"What restriction is stated in the instructions to candidates?","Question",{"text":79,"@type":80},"Candidates must not remove OET material from the test room.","Answer",{"name":82,"@type":77,"acceptedAnswer":83},"What does the candidate declaration require regarding test content?",{"text":84,"@type":80},"By signing, candidates agree not to disclose or use any OET test or sub-test content except to take the test, and not to assist others to disclose or use it.",{"name":86,"@type":77,"acceptedAnswer":87},"How is cellulitis severity classified in the booklet?",{"text":88,"@type":80},"It uses Classes I to IV, ranging from no systemic toxicity (Class I) through systemic unwell states with comorbidity (Class II), significant systemic upset or vascular-compromised limb infection (Class III), to severe life-threatening infections like necrotizing fasciitis (Class IV).","https://schema.org",{"og:url":51,"og:type":91,"og:title":13,"og:site_name":62,"og:description":14},"article",{"robots":93,"canonical":51},"index,follow",{"doc_id":7,"site_id":23},{"code":4,"msg":5,"data":96},[97,101,105,108,113,118,123,128,133,136,139],{"id":20,"doc_module":4,"doc_module_name":45,"category_name":98,"show_sort_weight":99,"slug":100},"Story & Novel",90,"story-novel",{"id":46,"doc_module":4,"doc_module_name":45,"category_name":102,"show_sort_weight":103,"slug":104},"Literature",80,"literature",{"id":11,"doc_module":4,"doc_module_name":45,"category_name":12,"show_sort_weight":106,"slug":107},70,"exam",{"id":109,"doc_module":4,"doc_module_name":45,"category_name":110,"show_sort_weight":111,"slug":112},5,"Comic",60,"comic",{"id":114,"doc_module":4,"doc_module_name":45,"category_name":115,"show_sort_weight":116,"slug":117},6,"Technology",50,"technology",{"id":119,"doc_module":4,"doc_module_name":45,"category_name":120,"show_sort_weight":121,"slug":122},7,"Healthcare",40,"healthcare",{"id":124,"doc_module":4,"doc_module_name":45,"category_name":125,"show_sort_weight":126,"slug":127},8,"Research & Report",30,"research-report",{"id":129,"doc_module":4,"doc_module_name":45,"category_name":130,"show_sort_weight":131,"slug":132},9,"Religion & Spirituality",20,"religion-spirituality",{"id":131,"doc_module":4,"doc_module_name":45,"category_name":134,"show_sort_weight":131,"slug":135},"World Cup","world-cup",{"id":28,"doc_module":4,"doc_module_name":45,"category_name":137,"show_sort_weight":28,"slug":138},"Lifestyle","lifestyle",{"id":140,"doc_module":4,"doc_module_name":45,"category_name":141,"show_sort_weight":109,"slug":142},19,"General","general"]